Smith & Nephew SNATS (NYSE:SNN) Sets New 52-Week Low – Should You Sell?

Smith & Nephew SNATS, Inc. (NYSE:SNN) reached a new 52-week low during trading on Thursday. The company traded as low as $26.38 and last traded at $26.4550, with a volume of 588841 shares changing hands. The stock had previously closed at $26.96.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on SNN shares. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Smith & Nephew SNATS in a research note on Thursday, August 6th. Zacks Research upgraded Smith & Nephew SNATS from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 8th. Barclays cut Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a research report on Wednesday, August 5th. Kepler Capital Markets lowered Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research report on Thursday, June 4th. Finally, Wall Street Zen raised Smith & Nephew SNATS from a “hold” rating to a “buy” rating in a research report on Sunday, September 13th. One analyst has rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $31.91.

Smith & Nephew SNATS Stock Performance

The business has a 50-day moving average price of $29.14 and a 200-day moving average price of $30.42. The company has a current ratio of 2.14, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62.

Smith & Nephew SNATS Announces Dividend

The firm also recently announced a dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 2nd will be given a dividend of $0.3120 per share. This represents a yield of 205.0%. The ex-dividend date of this dividend is Friday, October 2nd.

Institutional Investors Weigh In On Smith & Nephew SNATS

Several institutional investors have recently added to or reduced their stakes in SNN. Clearstead Trust LLC purchased a new position in shares of Smith & Nephew SNATS in the 2nd quarter valued at approximately $25,000. Addison Advisors LLC acquired a new position in Smith & Nephew SNATS during the 2nd quarter valued at approximately $43,000. Allworth Financial LP purchased a new position in shares of Smith & Nephew SNATS in the second quarter worth $48,000. Centaurus Financial Inc. purchased a new position in Smith & Nephew SNATS in the 2nd quarter worth $112,000. Finally, Global Retirement Partners LLC raised its stake in shares of Smith & Nephew SNATS by 811.6% in the fourth quarter. Global Retirement Partners LLC now owns 1,887 shares of the medical equipment provider’s stock worth $62,000 after purchasing an additional 1,680 shares during the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company headquartered in Watford, England. Founded in 1856 by pharmacist Thomas James Smith in Hull, the company has grown from a pharmacy business into a provider of surgical and wound-care products for healthcare professionals and patients.

The company operates through three principal areas: Orthopaedics, Sports Medicine, and Advanced Wound Management. Its products include joint-replacement systems, trauma and extremity devices, arthroscopy equipment, surgical repair technologies, wound dressings, negative-pressure wound therapy systems, and other products used to support healing and tissue recovery.

Smith & Nephew serves hospitals, clinics, surgeons, and patients in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific, and other international regions.